By Michael Susin
Prime Medicine shares rose on Monday after the company signed a research collaboration and license agreement Bristol Myers Squibb to develop reagents for T-cell therapies.
In premarket trading, shares were up 20% to $4.15. However, the stock is down more than 60% on a year-to-date basis through Friday's close.
The biotechnology company said it will develop optimized reagents for the next generation of ex vivo T-cell therapies, while Bristol Myers Squibb will be responsible for development, manufacturing and commercialization of the cell therapies.
Prime Medicine said it will receive a $55 million upfront payment and a $55 million investment from Bristol Myers Squibb. It will is also eligible to receive more than $3.5 billion in milestones, including up to $1.4 billion in development milestones and more than $2.1 billion in commercialization milestones, along with royalties on net sales.
The company added that it expects its cash runway to fund operations into the first half of 2026, and that it is seeking further partnership opportunities to advance other programs, including those for neurological diseases, cell therapy, ocular diseases and hearing loss.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
September 30, 2024 08:51 ET (12:51 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。